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Receptor for advanced glycation endproducts (RAGE) is a cell-surface receptor. The 
binding of ligands to membrane-bound RAGE (mRAGE) evokes cellular responses involved in 
various pathological processes. Previously, we identified a novel soluble form, endogenous 
secretory RAGE (esRAGE) generated by alternative 5’ splice site selection in intron 9 that leads 
to extension of exon 9 (exon 9B). Because esRAGE works as an antagonistic decoy receptor, 
the elucidation of regulatory mechanism of the alternative splicing is important to understand 
RAGE-related pathological processes. Here, we identified G-rich cis-elements within exon 9B 
for regulation of the alternative splicing using a RAGE minigene. Mutagenesis of the G-rich 
cis-elements caused a drastic increase in the esRAGE/mRAGE ratio in the minigene-transfected 
cells and in loss of binding of the RNA motif to heterogenous nuclear ribonucleoprotein 
(hnRNP) H. On the other hand, the artificial introduction of a G-stretch in exon 9B caused a 
drastic decrease in the esRAGE/mRAGE ratio accompanied by the binding of hnRNP H to the 
RNA motif. Thus, the G-stretches within exon 9B regulate RAGE alternative splicing via 
interaction with hnRNP H. The findings should provide a molecular basis for the development of 
medicines for RAGE-related disorders that could modulate esRAGE/mRAGE ratio. 
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Alternative splicing is one of the mechanisms that eukaryotes have developed to 
generate a wider diversity of gene products. In humans, as much as 74% of all genes are 
estimated to employ this particular mechanism (1). The functions of protein products and 
consequent cellular phenotypes can also be regulated by alternative splicing. In some cases, 
alternative splicing even yields protein variants with reciprocal functions, such as 
signal-transducing agonistic membrane receptors versus their antagonistic decoy counterpart (2). 
The production of physiologically antagonistic variants by alternative splicing applies to the 
pre-mRNA of receptor for advanced glycation endproducts (RAGE), which experiences 
alternative 5' splice site selection in intron 9 to produce membrane-bound RAGE (mRAGE) or 
endogenous secretory RAGE (esRAGE) (3, 4). mRAGE is a multi-ligand receptor that has an 
extracellular region, consisting of a V-type and two C-type immunoglobulin-like domains, a 
transmembrane region, and a short C-terminal intracellular portion (5, 6). The V-domain of 
RAGE is critical for the binding of various ligands, including advanced glycation endproducts 
(AGE) (5, 6), S100 (7), amyloid β (8), Mac-1 (9), and high-mobility group box-1 
(HMGB1)/amphoterin (10, 11). The intracellular signals evoked by the binding of these ligands 
have been implicated in diabetic vascular complications (12, 13), proinflammatory reactions (6, 
9), neurodegenerative disorders (8), and cancer (11). Human esRAGE was identified through an 
analysis of vascular cell-derived polysomal RNA to be a soluble-form splice variant of RAGE 
(3), which is produced by the utilization of an alternative downstream 5’ splice site in intron 9 
that leads to the extension of exon 9 and skipping of exon 10. The extended 82-nucleotide 
sequence of exon 9, which is designated as exon 9B, contains an in-frame stop codon and gives 
a unique amino acid sequence to the C-terminus of esRAGE that lacks the transmembrane 
domain (Fig. 1). esRAGE is considered to act as a modulating factor opposing the 
mRAGE-associated conditions in various diseases mentioned above. In fact, accumulating 
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evidence indicates that in patients with some diseases, such as atherosclerosis and diabetic 
retinopathy, plasma esRAGE levels are significantly lower than those in control groups (14, 15), 
and supports the view that low levels of circulating esRAGE may cause vulnerability to these 
diseases. Therefore, elucidation of the regulatory mechanism would provide a molecular basis for 
the development of drugs that can induce cytoprotective esRAGE but suppress cytotoxic mRAGE. 
Here, we investigated the molecular mechanisms for regulation of the RAGE alternative 
splicing by mutagenesis approach using a RAGE minigene. 
In the present study, we identified G-rich cis-elements within exon 9B, which are 
essential for the preferential utilization of the upstream mRAGE 5’ splice site. Furthermore, we 
demonstrated that heterogenous nuclear ribonucleoprotein (hnRNP) H binds to cis-elements in a 
G-stretch-dependent manner. These results suggested that the functions of the cis-elements are 
mediated through interaction with cellular hnRNP H. Taken together, these results suggested 
that the binding of hnRNP H to G-stretches in exon 9B of RAGE pre-mRNA causes preferential 






Human microvascular endothelial cells (HMVEC) (KURABO) were maintained in 
HuMedia-MV2 (KURABO), in accordance with the supplier’s instructions, in humidified 
incubators containing 5% CO2. The human embryonic kidney cell-derived cell line HEK293T 
was maintained in Dulbecco's modified Eagle's medium (Nissui) supplemented with 10% fetal 




esRAGE-specific rabbit polyclonal antibody was raised against the unique C-terminal 
16-amino-acid peptide (3). mRAGE-specific rabbit polyclonal antibody was raised against 
17-amino-acid peptide (amino acids 364-380, QRRQRRGEERKAPENQE) that corresponded to 
the cytoplasmic domain. These antibodies were affinity purified. Anti-GFP rabbit polyclonal 
antibody from Abcam, anti-hnRNP H rabbit polyclonal antibody from Bethyl Laboratories, 
anti-hnRNP H goat polyclonal antibody and anti-GAPDH monoclonal antibody from Santa 
Cruz Biotechnology were purchased. 
 
Construction of RAGE minigene 
A RAGE minigene was constructed by insertion of a 3’ part of the human RAGE 
genomic sequence and a fragment coding for the human RAGE signal sequence into a 
mammalian expression plasmid pEGFP-N1 (Clontech). PCR amplification of RAGE genomic 
sequence was accomplished using the cosmid clone KS71 (16) as a template, which was kindly 
provided by Professor Toshimichi Ikemura (Nagahama Institute of Bio-Science and Technology, 
Nagahama, Japan). A RAGE genomic sequence from the 3’ part of exon 8 to the 3’ flanking 
region of exon 11 (nucleotides 8572-9960 of GenBank D28769), including the polyadenylation 
signal, was amplified and inserted in-frame 3’ to the very end of the EGFP-coding region of 
pEGFP-N1 using restriction enzymes BsrGI and AflII. For amplification of the fragment coding 
for the human RAGE signal sequence (nucleotides 1-101 of GenBank AB036432), the 
full-length RAGE cDNA (3) was used as a template and the amplified fragment was inserted 
into pEGFP-N1 in-frame using restriction enzymes EcoRI and AgeI in the multiple cloning site 
at 5’ of EGFP-coding region (Fig. 2). Three-nucleotide substitutions were introduced by PCR in 
accordance with the procedures described previously (17). All amplified inserts were 




HEK293T cells were transfected with RAGE minigene constructs using FuGENE 6 
(Roche). HMVEC were transfected with RAGE minigene constructs using a Microporator 
MP-100 electroporation device (Digital Bio Technology) following the manufacturer’s 
instructions. Briefly, trypsinized HMVEC cells were washed with PBS, pelleted, and 
resuspended in the Resuspension Solution supplied by the manufacturer. RAGE minigene 
constructs were added to the cell suspension and mixed well. Then, transient electrical pulses 
optimized for HMVEC were applied to the cell-DNA mixture in an electrode tip on the device 
followed by immediate transfer to complete growth medium. Forty-eight hours after 
transfection, the cells were examined for the production of RAGE splice variants by Western 
blotting or quantitative reverse transcription PCR (qRT-PCR). 
 
Western Blotting 
Forty-eight hours after transfection, HMVEC or HEK293T cells were washed with 
cold PBS, then cells were lysed immediately in SDS-polyacrylamide gel electrophoresis 
(PAGE) sample buffer [62.5 mM Tris-HCl (pH 6.8), 2% SDS and 10% glycerol]. After 
determination of protein concentrations using a BCA protein assay kit (Pierce) using BSA as a 
standard, dithiothreitol and bromophenol blue were added to final concentrations of 100 mM 
and 0.001% (w/v), respectively. Cell lysates containing 2 µg protein were resolved by 
SDS-PAGE, and then transferred onto an Immobilon-FL membrane (Millipore). The membrane 
was treated with primary antibodies and then incubated with 1:3000 diluted horseradish 
peroxidase-conjugated anti-rabbit IgG (GE Healthcare). The immunoreactive bands were 
visualized using an ECL detection system (GE Healthcare) and exposure to X-ray film. For 
quantification of the intensity of immunoreactive bands, 1:10000 diluted infrared fluorescent 
dye-labeled anti-rabbit and anti-mouse IgG antibody (LI-COR) were used as secondary 
antibodies and the immunoreactive bands quantified using an Odyssey infrared fluorescence 
imaging system (LI-COR). 
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Quantification of RAGE splice variants by multiplex qRT-PCR 
Total RNA was isolated from HMVEC using RNeasy Plus Mini Kit (QIAGEN). The 
sequences of the primers and probes used for the multiplex qRT-PCR assay are listed in Table 1. 
The probes were labeled with different fluorochromes as follows; the mRAGE probe was 
labeled with FAM and quenched with Black-Hole-Quencher (BHQ) 1; the esRAGE probe was 
labeled with Quasar 670 and quenched with BHQ2; the GAPDH probe was labeled with CAL 
Fluor Orange 560 and quenched with BHQ1. All primers and probes were synthesized by 
Biosearch Technologies. 
For qRT-PCR, total RNA were reverse transcribed in 20 µl of reaction mixture using 
an AffinityScript QPCR cDNA Synthesis Kit (Stratagene Products Division, Agilent 
Technologies). For cDNA synthesis, random hexamers were used as primers. The multiplex 
real-time PCR assay was performed to measure both mRAGE and esRAGE in a total reaction 
mixture (25 µl) containing 2 µl of cDNA mixture, 12.5 µl of 2×BrilliantII QPCR Master Mix 
(Stratagene Products Division, Agilent Technologies), primers and probes. 
The probes were designed for the variant-specific exons, and primers were designed 
for the boundary of common and variant-specific exons. Primer and probe concentrations in 
qRT-PCR were optimized as follows: 100 nM each for forward and reverse primers for mRAGE 
and for esRAGE, 900 nM each for forward and reverse primers for GAPDH, 100 nM each for 
probes for mRAGE and for esRAGE, and 200 nM for probe for GAPDH. Amplification and 
real-time fluorescence detection were performed using a model Mx3005P Real Time QPCR 
system (Stratagene Products Division, Agilent Technologies) and the following protocol: an 
initial denaturation and polymerase activation step for 10 min at 95°C, followed by 40 cycles of 
95°C for 30 s and 60°C for 1 min. Serial dilution of mRAGE and esRAGE plasmid standards 
was used to construct each standard curve, and the linear range where the standard curve was 
not affected by the presence of an excessive amount of counterpart plasmid (esRAGE for 
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mRAGE quantification and mRAGE for esRAGE quantification, respectively) was determined. 
In this way, four orders of magnitude (1×102 to 1×106 copies) of the linear range in the presence 
of 1×105 copies of counterpart were able to be defined for the quantification of each product. 
The mRNA expression levels of mRAGE and esRAGE were normalized using GAPDH. 
 
RNA immunoprecipitation (RIP) followed by RNA electrophoretic mobility shift assay 
(REMSA) 
The sequences of the infrared fluorescent dye-labeled RNA synthetic oligonucleotides 
used as probes for the REMSA assay are listed in Table 2. Nuclear extracts were prepared from 
HEK293T cells as described previously (18). RNA binding reactions were performed in a final 
volume of 25 µl containing 400 ng of synthetic RNA oligonucleotides labeled by Alexa Fluor 
680 at the 5’ end, 50 µg of nuclear extract, 40 units of RNasin Ribonuclease Inhibitor (Promega), 
and 11.3 µg of tRNAs (Invitrogen) in buffer composed of 10 mM HEPES, 1 mM dithiothreitol, 
120 mM KCl, 3 mM MgCl2, and 5% glycerol. The reaction mixtures were incubated at 4°C for 
20 min followed by 7 min of UV cross-linking. After UV cross-linking, the hnRNP 
H-containing complexes were isolated by immunoprecipitation as follows; The reaction mixture 
was mixed with 75 µl of PBS containing 0.1% Tween 20 (PBS-T) and incubated with 20 µl of 
Protein G Sepharose 4 Fast Flow (GE Healthcare) precoated with anti-hnRNP H rabbit 
polyclonal antibody at 4°C for 2 to 3 hours. The pellets were washed with PBS-T three times 
and the protein-RNA complexes were eluted by boiling the pellet in SDS-PAGE sample buffer. 
Control immunoprecipitation was carried out using normal rabbit IgG. Samples were separated 
by a 10% polyacrylamide gel and were transferred onto an Immobilon-FL membrane 
(Millipore). The membrane was subjected to Western blotting using anti-hnRNP H goat 
polyclonal antibody and fluorescent secondary antibody whose fluorescence could be 
discriminated from Alexa Fluor 680 used for the RNA probe. The fluorescent bands were 










The RAGE minigene replicates RAGE alternative splicing 
To investigate regulatory elements in the alternative splicing of human RAGE 
transcripts, we constructed a minigene that contains the RAGE gene segment from the 3’ part of 
exon 8 to the 3’ flanking region of exon 11 and the EGFP gene, so that they would yield 
EGFP-RAGE fusion proteins (Fig. 2A). The minigene was transfected into HEK293T cells, and 
expression levels of mRAGE-type and esRAGE-type splicing products were analyzed by 
Western blotting using anti-GFP antibody, mRAGE-specific antibody and esRAGE-specific 
antibody. As shown in Fig. 2B, both mRAGE- and esRAGE-type splicing products were 
detected in the minigene-transfected HEK293T cells. Direct fusion of EGFP domain to exon 9 of 
human RAGE gene resulted in aberrant splicing, and mutagenesis at 3’ splice signal elements in 
intron 8, such as branch point consensus motif and polypyrimidine tract, resulted in skip of exon 9 
(data not shown). These results indicated the necessity of intron 8 for replication of the alternative 
splicing. 
 
G-stretches in exon 9B function as cis-elements for preferential utilization of the upstream 
mRAGE 5’ splice site 
We introduced a series of 3-nucleotide substitutions to sites 4-8, purine-rich and 
pyrimidine-rich sequences in exon 9B of the RAGE minigene construct (Fig. 3A). Using this 
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method, the sequences were mutated without affecting the short distance between the two 
alternative 5’splice sites in intron 9, thus minimizing the effects of the distance. The five sites 
were selected so as not to overlap with the minimal binding site of U1 snRNP (-6 to +10 relative 
to the splice junction) (19, 20). 
Four out of the 5 mutations in exon 9B had profound impacts on the regulation of 
RAGE splicing in HEK293T cells (Fig. 3, B and C). Mutations replacing G-triplets with 
C-triplets (mut4, mut6 and mut7) significantly increased the %esRAGE (percentage of 
esRAGE-type product in the sum of esRAGE-type and mRAGE-type products); 83.1% for mut4, 
99.8% for mut6, and 97.8% for mut7, while the value for the wild-type sequence was 70.2%. 
Especially in the case of mut6, the mRAGE-type product was barely detected. On the other 
hand, replacement of a C-triplet in the middle of a 5-nucleotide C-stretch by a G-triplet (mut5) 
caused a drastic decrease in %esRAGE to 9.3%. The effect of mutation of a purine tract GAA to 
a pyrimidine tract CTT (mut8) were marginal (66.4%). 
 
G-stretches in exon 9B function in HMVEC in the same manner as in HEK293T cells 
Next, we investigated whether or not the function of the cis-elements were dependent 
on cell type by introducing the same set of exon 9B-mutated minigenes into primary endothelial 
cells, HMVEC, because the AGE-RAGE axis in the vascular endothelial cell is considered to be 
a very important factor in the progression of diabetic angiopathy. To achieve high transfer 
efficiency in the primary cultured cells, we relied on an MP-100 electroporation device. After 
optimization of the conditions using pEGFP-N1, EGFP expression in 70% or more of HMVEC 
was observed (data not shown). 
The quantification of the splice variants by Western blotting using an anti-GFP 
antibody showed the %esRAGE (63.0%) of wild-type minigene-transfected cells, which was 
similar to that of HEK293T (70.2 %), and similar effects of each mutation on %esRAGE as in 
the case of HEK293T cells were observed (Fig. 4, A and B). Results of direct fluorescence 
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imaging of the minigene-derived products in cells were consistent with the predominant 
production of mRAGE-type product from the mut5 minigene and the predominant production of 
esRAGE-type product from the mut6 minigene (Supplementary Fig. S1). 
Furthermore, we analyzed the relative quantity of mRNA corresponding to mRAGE- 
and esRAGE-type by multiplex qRT-PCR using TaqMan probes (Fig. 4, C and D). 
The %esRAGE of wild-type minigene-derived products was 11.8%, indicating that the mRAGE 
5’ splice site is preferentially utilized. This was consistent with the results of qRT-PCR analysis 
of endogenous RAGE transcripts, in which the %esRAGE was 2.8% (Supplementary Fig. S2). 
The direction of the effect of each mutation on %esRAGE at the mRNA level was identical to 
that at the protein level. The three mutations mut4, mut6, and mut7, in which G-triplets were 
replaced by C-triplets, showed significant increases in %esRAGE (37.8% for mut4, 99.6% for 
mut6, and 80.8% for mut7) compared with the wild-type. Mutation mut5, in which a C-triplet 
was replaced by a G-triplet, showed a drastic decrease in %esRAGE to 0.1%. No significant 
effect of mut8 on the alternative splicing was observed. 
It should be noted that the esRAGE/mRAGE ratios observed at the mRNA level were 
generally lower than those observed at the protein level in all minigene experiments. This could 
be at least partly ascribed to the rapid removal of mRAGE protein from the cell surface due to 
shedding by proteases (21-23). 
 
hnRNP H specifically binds the G-stretches in exon 9B 
Sites 6 and 7 comprise a 6-nucleotide G-stretch, and similar G-rich sequences have 
been identified as the signature of binding sites for hnRNP H family proteins (24-26). To assess 
the ability of hnRNP H to bind to this sequence, we examined complex formation of fluorescent 
dye-labeled RNA probes and hnRNP H in a nuclear extract of HEK293T cells by RIP followed 
by REMSA (Table 2 and Fig. 5). To minimize artifactual results caused by non-specific 
cross-reaction of the antibody, different anti-hnRNP H antibodies were used for the 
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immunoprecipitation and for the Western blotting. 
Complex formation of hnRNP H and the RNA probe encompassing sites 6 and 7 was 
observed, and the binding disappeared following replacement of GGG by CCC at sites 6 and 7 
(Fig. 5, site 6-7). These results demonstrated that hnRNP H binds the wild-type sequence of 
sites 6-7, and that the G-stretch that resides therein is essential for the interaction. 
The importance of the G-stretch in exon 9B for the interaction with hnRNP H was 
further supported by the results with RNA probes encompassing site 5; the wild-type sequence 
did not bind hnRNP H, and replacement of CCC by GGG caused the binding of the RNA and 
hnRNP H (Fig. 5, site 5). Therefore, these results indicated that hnRNP H binds to the RNA 
probe in a sequence-dependent manner, and that, in particular, the G-stretch is important for 
hnRNP H binding. The site 8 probe, either wild-type sequence or mutated sequence, barely 





In this study, we identified G-rich cis-elements in exon 9B that are essential for the 5’ 
splice site selection in intron 9 of the RAGE pre-mRNA and demonstrated the involvement of 
hnRNP H as a regulatory protein that interacts with these cis-elements. 
We introduced a series of 3-nucleotide substitutions to sites 4-8 in exon 9B of a RAGE 
minigene construct (Fig. 3A). The effects of each mutation on RAGE alternative splicing were 
similar between HEK293T cells (Fig. 3, B and C) and HMVEC (Fig. 4). The mutations of the 
G-stretch at site 6-7 nearly abrogated the production of mRAGE. Mutation of the G-triplet at 
site 4 also significantly decreased the mRAGE-type product but the effect was less than those 
for site 6-7. Notably, the introduction of an additional G-triplet in place of a C-triplet at site 5 
caused preferential utilization of the mRAGE 5’ splice site. The number of G-triplets in exon 9B 
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appeared to correlate with the extent of utilization of the mRAGE 5’ splice site. The results were 
similar to the case of artificially duplicated 5’ splice sites of the human α-globin gene intron 2, 
in which G-triplets flanked by the two alternative 5’ splice sites activate the upstream site and 
the number of the G-triplets correlated with the extent of the activation (27). 
The sequences of the G-rich cis-elements identified in the present study, sites 4 and 
site 6-7 matched the consensus motif of the binding site of hnRNP H family proteins, DGGGD 
(where D is U, G, or A) (24). The hnRNP H family is composed of hnRNPs H1, H2, F, 2H9, and 
GRSF-1, which are highly homologous, ubiquitously expressed proteins that have RNA 
recognition motifs. They have been implicated in RNA processing such as splicing, 
polyadenylation, capping, and transport of RNA (24). hnRNP H has also been reported to be 
involved in the regulation of 5’ splice site selection in Bcl-xS/Bcl-xL (2) and DM20/PLP (28, 
29). In both cases, the G-rich cis-elements were identified within the region between the two 
alternative 5’splice sites, as in the case of G-rich cis-elements in RAGE exon 9B. The results of 
mutant minigene experiments in this study are in accord with the reports that the disruption of 
G-rich cis-elements abolished the binding of hnRNP H and led to preferential utilization of the 
downstream 5’ splice site in Bcl-xS/Bcl-xL (2) and in DM20/PLP transcripts (29). 
To examine whether the G-rich cis-elements in exon 9B bind to hnRNP H, we carried 
out RIP followed by REMSA. The results of the binding assay clearly showed that the RNA 
probe encompassing the G-stretch at site 6-7 bound to hnRNP H. Continuity of the G-stretch 
may be important in this particular region because mutations at sites 6 (mut6) and 7 (mut7) 
resulted in drastic decreases in hnRNP H binding even though 3 out of the 6 guanine nucleotides 
in the stretch were still preserved in both mutated sequences (Fig. 5, site 6-7). On the other hand, 
the introduction of a G-triplet in the place of a C-triplet at site 5 (mut5) conferred affinity for 
hnRNP H (Fig. 5, site 5). Although the mutated sequence at site 5, CGGGC does not match the 
best motifs for binding, an intermediate affinity by hnRNP H has been described (24). 
Because the G-rich cis-elements in exon 9B were essential both for preferential 
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utilization of the mRAGE 5’ splice site and for the binding to hnRNP H, we hypothesized that 
the cis-elements regulate 5’ splice site selection via interaction with hnRNP H, either by 
promoting utilization of the mRAGE 5’ splice site or inhibiting use of the esRAGE 5’ splice site. 
The skipping of exon 10 in esRAGE-type splicing may be ascribed to the limitation of 
intron length in higher eukaryotes. Roughly 45 nucleotides must separate the 5’ splice site and 
branch point (30-34), and the minimum distance between the branch point and 3’ splice site 
appears to be approximately 18 nucleotides (30, 35), respectively. Therefore introns shorter than 
70 nucleotides are extremely rare in mammals and cannot be spliced out efficiently (36). When 
the esRAGE 5’ splice site in intron 9 is selected, the distance between this site and the 3’ splice 
site that borders exon 10 is 46 nucleotides, which is considerably shorter than the lower limit of 
the intron length. Therefore, the use of the downstream, esRAGE 5’ splice site of intron 9 and 
the inclusion of exon 10 would be mutually exclusive. This notion may be supported by the 
report by Hudson et al. (37), which analyzed human RAGE splice variants. Among the 20 splice 
variants analyzed, all variants that used the downstream esRAGE 5’ splice site in intron 9 
skipped exon 10; in contrast, all variants that used the upstream mRAGE 5’ splice site in intron 
9 included exon 10. Thus, the available evidence indicates that the selection of either one of the 
two alternative 5’ splice sites in intron 9 is the most likely the key event of RAGE alternative 
splicing, which couples with inclusion or exclusion of exon 10. 
The regulation of RAGE alternative splicing is also important from the clinical 
viewpoint, because it has been suggested that RAGE signaling is involved in a wide range of 
pathologies and disorders, such as diabetes (12, 13), Alzheimer’s disease (8), and cancer (11), 
and because the balance of expressions of the two RAGE products generated by alternative 
splicing, cytotoxic mRAGE and cytoprotective esRAGE, is considered to be associated with 
susceptibility/resistance to these RAGE-related disorders. A few drugs have been reported to 
affect serum levels of esRAGE. Angiotensin converting enzyme-1 inhibitors (ACEI) 
purportedly increase esRAGE mRNA expression and decrease membrane-bound RAGE mRNA 
 16 
expression in cultured bovine aortic endothelial cells and in the renal cortex of diabetic mice 
(38). An increase in esRAGE has been observed in ACEI-treated (38) and 
thiazolidinedione-treated diabetic patients (39). Elucidation of the regulatory mechanism of 
RAGE alternative splicing may pave the way for the development of drugs that can induce 
esRAGE but suppress mRAGE and could be promising candidates of preventive or curative 
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Fig. 1 Schematic representation of the human RAGE gene and its alternative splicing 
products. 
(A) Organization of the human RAGE gene (16). Open and closed boxes indicate exons and 
introns, respectively. (B) The membrane-bound form of RAGE (mRAGE) and the secretory 
form of RAGE (esRAGE). Hatched boxes indicate the signal sequence and transmembrane 
domain, and shaded boxes indicate the coding regions of the mRNA. These alternatively spliced 
mRNAs are generated by alternative 5’ splice site selection in intron 9. 
 
Fig. 2 RAGE minigene construct and its products 
(A) Human RAGE minigene construct and the mRAGE- and esRAGE-type products. Middle 
panel shows a schematic representation of the EGFP-human RAGE fusion minigene. Hatched 
boxes indicate the signal sequence and transmembrane domain. Shaded boxes indicate the 
coding sequence for EGFP. Black boxes indicate exon 9B. The first and last nucleotides of 
RAGE exons are numbered (the nucleotide numbers are based on the genomic sequence starting 
from the first ATG of exon 1). Top and bottom panels show mRNA products generated by 
mRAGE-type splicing and esRAGE-type splicing, respectively. (B) Representative Western blot 
of minigene-transfected HEK293T cell lysate. Anti-GFP antibody detected both type products. 
The anti-esRAGE antibody raised against the unique C-terminal sequence of esRAGE 
specifically detected the esRAGE-type product. The anti-mRAGE antibody raised against the 
cytoplasmic domain of mRAGE specifically detected the mRAGE-type product. 
 
Fig. 3 Effects of mutagenesis in exon 9B on the alternative splicing in HEK293T 
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(A) Wild-type nucleotide sequence of exon 9B and the 5 mutations introduced into the minigene. 
Arrows indicate the 5’ splice sites of mRAGE- and esRAGE-type splicing. The last nucleotides 
of exon 9 and exon 9B are numbered (the nucleotide numbers are based on the genomic 
sequence starting from the first ATG of exon 1). Capitals “TGA” indicate in-frame stop codon. 
In the wild-type sequence, nucleotides targeted for the substitutions are underlined. Dotted line 
between site 6 and site 7 indicates the boundary of the two target sites. (B) Quantification of 
esRAGE-type (open bar) and mRAGE-type (closed bar) protein products by Western blotting 
using anti-GFP antibody. All data were normalized by the intensity of GAPDH used as an 
internal control. Bars indicate mean ± SD (n=6). (C) %esRAGE (percentage of esRAGE-type 
product in sum of esRAGE-type and mRAGE-type product) was calculated from (B). Bars 
indicate mean ± SD (**, p<0.01; *, p<0.05 vs wild-type). 
 
Fig. 4 Effects of mutagenesis in exon 9B on alternative splicing in HMVEC 
 (A) Quantification of esRAGE-type (open bar) and mRAGE-type (closed bar) protein 
products by Western blotting using anti-GFP antibody. All data were normalized by the intensity 
of GAPDH used as an internal control. Bars indicate mean ± SD (n=6). (B) Values 
of %esRAGE at the protein level were calculated from (A). Bars indicate mean ± SD (**, 
p<0.01 vs wild-type). (C) qRT-PCR quantification of esRAGE-type (open bar) and 
mRAGE-type (closed bar) RNA products. All data were normalized using GAPDH mRNA 
levels. Bars indicate mean ± SD (n=3). (D) Values for %esRAGE at the mRNA level were 
calculated from (C). Bars indicate mean ± SD (**, p<0.01 vs wild-type). 
 
Fig. 5 hnRNP H binding to RNA sequences in exon 9B in a G-stretch-dependent manner. 
HEK293T cell nuclear extracts were subjected to RIP followed by REMSA with fluorescent 
dye-labeled RNA oligonucleotide probes (nucleotide sequences of probes are indicated in Table 
2). UV-crosslinked RNA-protein complexes were transferred to PVDF membrane and detected 
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by anti-hnRNP H antibody using an Odyssey system. (A) Fluorescence of the RNA probes is 
shown in red. (B) The hnRNP H-immunoreactive bands are shown in green. (C) In overlay 
images of (A) and (B), the complex of the RNA probe and hnRNP H appeared as retarded 
yellow bands, and unbound hnRNP H appeared as fast migrating green bands. Closed 
arrowheads indicate RNA-protein complexes, and open arrowheads indicate unbound hnRNP H. 
wt, probe with wild-type sequence; mut, probe with mutations; N, IP with normal rabbit IgG; H, 
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Forward primer for esRAGE  5’-ggccaactgcaggtgag-3’ 
Reverse primer for esRAGE 5’-ttttctggggccttccattc-3’ 
Probe for esRAGE 5’-Quasar 670-cttccctgactttatcaaacccctcacc-BHQ2-3’ 
Forward primer for mRAGE 5’-caggctctgtgggaggatc-3’ 
Reverse primer for mRAGE 5’-ggccttcctctcctctcct-3’ 
Probe for mRAGE 5’-FAM-acagccgccctgctcattgg-BHQ1-3’ 
Forward primer for GAPDH 5’-gttcgacagtcagccgcat-3’ 
Reverse primer for GAPDH 5’-aaatccgttgactccgacctt-3’ 
Probe for GAPDH 5’-CAL Fluor Orange 560-tttgcgtcgccagccgagc-BHQ1-3’ 
Table 2 Probes used for REMSA 
Mutated nucleotides are underlined. The nucleotide numbers are based on the genomic 
sequence starting from the first ATG of exon 1. 
 
Probe Sequence                  Nucleotide number 
Site 5 wild-type 5’-aagauagcccccaacacaug-3’     (2649-2668) 
Site 5 mutant 5’-aagauagcgggcaacacaug-3’ 
Site 6-7 wild-type 5’-ugugacuggggggaugguca-3’     (2667-2686) 
Site 6 mutant 5’-ugugacucccgggaugguca-3’ 
Site 7 mutant 5’-ugugacugggcccaugguca-3’ 
Site 8 wild-type 5’-gucaacaagaaaggaauggu-3’     (2683-2702) 
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Human RAGE gene 
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wt wt mut5 wt wt mut6 mut7 wt wt mut8 
site 5 site 6-7 site 8 
N H H N H H H N H H IP antibody 
Figure 5
Table S1 Primers used for the construction of RAGE minigenes. 
Mutated nucleotides are underlined in the sequences of primers used for mutagenesis. 
 
Primer Sequence 
For amplification of the genomic sequence   
    RAGE-F 5’-gatgtacaacagctgtgtggccacccat-3’ 
    RAGE-R 5’-gacttaagggtgaggttgtgtctcatac-3’ 
For amplification of the signal sequence  
    SS-F  5’-gagaattcgccaggaccctggaaggaagca-3’ 
    SS-R 5’-gaaccggtatgttttgagcacctactac-3’ 
For 3-nucleotide mutagenesis  
    GFP-F  5’-tgagcaaagaccccaacga-3’ 
    Mut4-R 5’-cttctgcttgggtgacttta-3’ 
    Mut5-R 5’-catgtgttgcccgctatctt-3’ 
    Mut6-R 5’-gaccatcccgggagtcacat-3’ 
    Mut7-R 5’-gttgaccatgggcccagtca-3’ 
    Mut8-R 5’-accattcctaagttgttgac-3’ 
    BsrGIm-F  5’-gacgagctgaacagctgtgt-3’ 
    AflII-R 5’-cgatttcggcctattggtta-3’ 





Fig. S1 Subcellular localization of mRAGE- and esRAGE-type products in HMVEC.
HMVEC were transfected with either wild-type or mutant minigenes, plated on 35-mm dishes
with glass coverslip windows (Corning), and cultured for 48 hours. Live imaging of the cells
detecting fluorescence of the EGFP domain of the minigene-derived products was performed
using a Carl Zeiss LSM510 META confocal imaging system equipped with a 30-milliwatt argon
laser and a 63×1.4 NA oil immersion objective.
Representative images of HMVEC transfected with the wild-type minigene (A,D,G), mut5
minigene (B,E,H), and mut6 minigene (C,F,I) are shown. Fluorescent images (A,B,C) and
transmission images (D,E,F) are merged (G,H,I). Cell margins observed in transmission images
are indicated by yellow dotted lines. The esRAGE-type product, which is dominant in mut6
minigene-transfected cells, is observed as perinuclear fluorescence. The mRAGE-type product,
which is dominant in mut5 minigene-transfected cells, is observed as diffuse fluorescence
bordering the cell margin in addition to perinuclear fluorescence. Wild-type minigene-transfected





























Fig. S2 Quantification of endogenous esRAGE and mRAGE mRNA in HMVEC.
Quantification of esRAGE (open bar) and mRAGE (closed bar) RNA products in
untreated HMVEC by qRT-PCR. Bars indicate averages of two independent experiments.
All data were normalized using GAPDH mRNA levels. The unit of the vertical axis is
compatible with that of Fig. 4 C. The calculated %esRAGE was 2.8%.
